Combiotic™: antimicrobial solution for dry cow mastitis treatment

Overview

Combiotic™ is a novel antimicrobial treatment developed specifically to address mastitis in dry cows, a critical period for dairy cattle. By targeting bacterial cell membranes, which are distinct from mammalian cells, Combiotic™ ensures strong selectivity and safety. It not only reduces bacterial load and inflammation but also boosts glutathione levels in host cells, providing additional antioxidant and anti-inflammatory benefits. The solution has been validated in vitro against major mastitis pathogens and confirmed for safety in third-party biocompatibility and toxicity studies.

Technical specifications

Key features:

• Targets and disrupts bacterial cell membranes, minimizing impact on mammalian cells
• Demonstrates broad-spectrum antimicrobial, antibiofilm, antioxidant, and anti-inflammatory activity
• Validated in over 18,000 preclinical tests against mastitis pathogens
• Avoids milk withdrawal and antibiotic residues, addressing antibiotic resistance concerns
• Proposed to be tested in a dry cow mastitis model involving non-lactating dairy cows, with efficacy assessed by bacterial clearance and inflammation reduction

Technology readiness level

Combiotic™ is currently at Technology Readiness Level 5, indicating that it has been validated in relevant environments and is ready for further clinical efficacy studies. This next phase will involve establishing a dry cow mastitis challenge model to evaluate its therapeutic potential under realistic field conditions.